




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Editorial

Cardiac injury after COVID-19: Primary cardiac and primary non-cardiac etiology makes a difference



With the coronavirus disease 2019 (COVID-19) pandemic entering now the third year, the multiple and devastating ways of the etiologic virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), involving the heart and cardiovascular system become more and more clearer [1].

The tremendous effort in research in combination with the numerous clinical observations sheds light on this complex and multifactorial interdependence. Therefore, today we can assume that cardiac injury associated with COVID-19 can result via direct or indirect mechanisms. Furthermore, we can distinguish between acute and post-recovery involvement of the cardiovascular system by the virus [2]. Another important facet of the pandemic is the associated collateral damage in the management of many other diseases. This includes all forms of heart diseases, not only the often issued delayed treatment of myocardial infarctions, has to be considered [3–5].

The direct mechanism involves Corona-virus infiltration into myocardial tissue, causing cardiomyocyte death and further fuel the inflammation process. Indirect mechanisms include stress on cardiac myocytes due to respiratory failure, hypoxemia and cardiac involvement secondary to severe systemic hyperinflammation [6].

In 2003, ACE2 was identified as the receptor for cell entering of SARS-CoV. SARS-CoV-2 also binds to ACE2 [1]. So, with the beginning of the COVID-19 pandemic the question arose, if there is some kind of interplay and further, whether or not the cardioprotective therapy with ACE/ARB in patients with heart failure should be discontinued. The latest, quite well conceived study by Bauer et al., showed no statistical significant interaction [7].

In addition, potential long-term cardiac sequelae of COVID-19-associated myocardial injury has been suggested [8]. Evidence of some kind of myocardial abnormalities were noted in a remarkably wide range, from 9% to 78%, of patients who recovered from acute COVID-19 [1]. Although more recent analyses suggest a lower incidence of long-term cardiac involvement.

Considering all the above-mentioned ways of cardiovascular involvement in the context of COVID-19 infections, it is of interest to know what the clinical implications are. The study by Khaloo et al. published in this issue of the *International Journal of Cardiology* provides further insights in this context. [9]. This well conducted multicenter retrospective cohort study included 2450 patients hospitalized for confirmed COVID-19 infection within a single hospital network between March and June 2020. The authors used a logistic regression analysis to identify predictors of mortality. Wide variability in some previous

studies that reported an impact of myocardial injury on mortality of patients with COVID-19 has been attributed to the small sample size and the differences in the definition of cardiovascular events. Due to the high sensitivity, with the accompanied, sometimes “false positive results”, troponin measurements alone do not allow to distinguish between a primary cardiac event leading to a biomarker elevation or a secondary cardiac event, precipitated by non-cardiac illness such as pulmonary disease, renal failure or sepsis [10].

In the current study, the authors showed that 57% of the study population had elevated high sensitive troponin (hs-TnT) levels. The comprehensive work-up and discrimination of the etiology of the troponin origin includes review of the primary data to confirm the ICD-10-CM code, furthermore putative changes in the 12-lead ECG and in the echocardiogram (e.g. wall motion abnormalities) pathologies. This analysis showed, that 653 (47%) of the 1401 patients with elevated hs-TnT levels in COVID-19 patients had a primary cardiac etiology (e.g. myocardial infarction), whereas 748 patients (53%) had a primary non-cardiac etiology such as renal failure ($n = 304$) or critical illness ($n = 286$). Remarkably, the mortality rate was significantly higher (OR 4.6, 95% CI: 2.7–7.6; $P < 0.001$) in patients with a primary cardiac etiology.

Taken together, this well performed analysis by Khaloo et al. stresses the extraordinary importance of cardiovascular care in COVID-19 patients and underlines that knowing the cause of the troponin etiology, helps not only to choose the right treatment but furthermore allows to predict more precisely the outcome of the given patient. Therefore, this paper has some potential implications on our daily cardiovascular-treatment of COVID-19 patients.

Declaration of Competing Interest

None.

References

- [1] M.K. Chung, D.A. Zidar, M.R. Bristow, S.J. Cameron, T. Chan, C.V. Harding 3rd, D. H. Kwon, T. Singh, J.C. Tilton, E.J. Tsai, N.R. Tucker, J. Barnard, J. Loscalzo, COVID-19 and cardiovascular disease: from bench to bedside, *Circ. Res.* 128 (8) (2021 Apr 16) 1214–1236, <https://doi.org/10.1161/CIRCRESAHA.121.317997> (Epub 2021 Apr 15. PMID: 33856918; PMID: PMC8048382).
- [2] H. Mejia-Renteria, A. Travieso, A. Sagir, E. Martínez-Gómez, A. Carrascosa-Granada, T. Toya, I.J. Núñez-Gil, V. Estrada, A. Lerman, J. Escaned, In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19, *Int. J. Cardiol.* 345 (2021 Dec 15) 153–155, <https://doi.org/10.1016/j.ijcard.2021.10.140> (Epub 2021 Oct 24. PMID: 34706286; PMID: PMC8542397).

DOI of original article: <https://doi.org/10.1016/j.ijcard.2021.12.029>.

<https://doi.org/10.1016/j.ijcard.2021.12.055>

Received 21 December 2021; Accepted 29 December 2021

Available online 1 January 2022

0167-5273/© 2021 Elsevier B.V. All rights reserved.

- [3] B. Metzler, P. Siostrzonek, R.K. Binder, A. Bauer, S.J. Reinstadler, Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage, *Eur. Heart J.* 41 (19) (2020 May 14) 1852–1853, <https://doi.org/10.1093/eurheartj/ehaa314> (PMID: 32297932; PMCID: PMC7184486).
- [4] S.J. Reinstadler, M. Reindl, I. Lechner, M. Holzknicht, C. Tiller, F.X. Roithinger, M. Frick, U.C. Hoppe, P. Jirak, R. Berger, G. Delle-Karth, E. Laßnig, G. Klug, A. Bauer, R. Binder, B. Metzler, Effect of the COVID-19 pandemic on treatment delays in patients with ST-segment elevation myocardial infarction, *J. Clin. Med.* 9 (7) (2020 Jul 10) 2183, <https://doi.org/10.3390/jcm9072183> (PMID: 32664309; PMCID: PMC7408681).
- [5] I. Lechner, M. Reindl, C. Tiller, M. Holzknicht, F. Troger, P. Fink, A. Mayr, G. Klug, A. Bauer, B. Metzler, S.J. Reinstadler, Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study, *Eur. Heart J.* (2021 Oct 11), ehab621, <https://doi.org/10.1093/eurheartj/ehab621> (Epub ahead of print. PMID: 34632491; PMCID: PMC8524546).
- [6] A. Akhmerov, E. Marbán, COVID-19 and the heart, *Circ. Res.* 126 (10) (2020 May 8) 1443–1455, <https://doi.org/10.1161/CIRCRESAHA.120.317055> (Epub 2020 Apr 7. PMID: 32252591).
- [7] A. Bauer, M. Schreinlechner, N. Sappeler, T. Dolejsi, H. Tilg, B.A. Aulinger, G. Weiss, R. Bellmann-Weiler, C. Adolf, D. Wolf, M. Pirklbauer, I. Graziadei, H. Gänzer, C. von Bary, A.E. May, E. Wöll, W. von Scheidt, T. Rassaf, D. Duerschmied, C. Brenner, S. Kääb, B. Metzler, M. Joannidis, H.U. Kain, N. Kaiser, R. Schwinger, B. Witznicher, H. Alber, F. Straube, N. Hartmann, S. Achenbach, M. von Bergwelt-Baildon, L. von Stülpnagel, S. Schoenherr, L. Forer, S. Embacher-Aichhorn, U. Mansmann, K.D. Rizas, S. Massberg, ACEI-COVID Investigators, Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial, *Lancet Respir. Med.* 9 (8) (2021 Aug) 863–872, [https://doi.org/10.1016/S2213-2600\(21\)00214-9](https://doi.org/10.1016/S2213-2600(21)00214-9) (Epub 2021 Jun 11. Erratum in: *Lancet Respir Med.* 2021 Aug 6; PMID: 34126053; PMCID: PMC8195495).
- [8] V.O. Puntmann, M.L. Carerj, I. Wieters, M. Fahim, C. Arendt, J. Hoffmann, A. Shchendrygina, F. Escher, M. Vasa-Nicotera, A.M. Zeiher, et al., Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19), *JAMA Cardiol.* 5 (2020) 1265–1273, <https://doi.org/10.1001/jamacardio.2020.3557> 2.
- [9] Khaloo P, Shaqdan A, Ledesma PA, Uzomah UA, Galvin J, Ptaszek LM, Ruskin JN. Distinct etiologies of high-sensitivity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19. *Int. J. Cardiol.* (in press).
- [10] A. Maino, E. Di Stasio, M.C. Grimaldi, L. Cappannoli, E. Rocco, R. Vergallo, F. Biscetti, S. Baroni, A. Urbani, R. Landolfi, L.M. Biasucci, Prevalence and characteristics of myocardial injury during COVID-19 pandemic: a new role for high-sensitive troponin, *Int. J. Cardiol.* 338 (2021 Sep 1) 278–285, <https://doi.org/10.1016/j.ijcard.2021.06.028> (Epub 2021 Jun 19. PMID: 34157355; PMCID: PMC8214325).

Bernhard Metzler*, Ivan Lechner, Martin Reindl, Sebastian

J. Reinstadler

University Clinic of Internal Medicine III, Cardiology and Angiology,
Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck,
Austria

* Corresponding author.

E-mail address: Bernhard.Metzler@tirol-kliniken.at (B. Metzler).